Background: Cardiovascular disease is the leading cause of morbidity and
mortality worldwide in developed countries, and its social and economic burden is
expected to increase dramatically over the next decades. Despite significative improvement
in the pharmacological treatment, and the huge advances in prevention, the
quest for new molecular targets and for novel, more efficient and personalized therapies
is still a priority for this group of pathologies.
Objective: The paramount complexity of the metabolic networks responsible for the
onset and progression of cardiovascular disease is highlighted by the wide and diverse
array of new molecular targets recently described in literature. In this brief review, we
focused our interest on a subset of promising molecular targets for the development of
new pharmacological treatments specific for cardiac diseases such as coronary artery
disease, heart failure and myocardial infarction.
Conclusion: The global quest for new molecular targets for the treatment of cardiac diseases
is leading to an impressive amount of records in the more recent literature. Although
several promising molecular pathways have been identified so far, great caution should be
used in considering all these targets effective in promoting the production of new drugs.
The identification of suitable therapeutic targets is in fact an ongoing challenge that
often lacks enough pre-clinical and clinical studies, which hinders the effective utilization
of several new drugs due to a lack of efficacy or induction of safety liabilities.